Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06046248 · ClinicalTrials.gov registry record · Phase 2

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Northside Hospital.

Recruiting
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT06046248 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 25 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06046248, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Northside Hospital.

RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • DRUG Rituximab
  • DRUG Belumosudil

Study Locations (1)

Georgia

  • Northside Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-01-29
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

Northside Hospital

26 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06046248

The ClinicalTrials.gov registry entry for NCT06046248 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (78% lower). The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.

NCT06046248 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT06046248 about?

NCT06046248 is a clinical study titled "Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease". This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

What is the current status of trial NCT06046248?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-01-29. Estimated completion is 2027-12-31.

What conditions does trial NCT06046248 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT06046248?

The interventions under investigation include: Rituximab (DRUG), Belumosudil (DRUG).

Who is sponsoring clinical trial NCT06046248?

This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06046248 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.